According to a study which appeared in the Journal of Clinical Investigation, a new version of a common antibiotic could eliminate the side effects associated with the drug—risk of hearing loss and kidney damage.
Aminoglycosides is the most commonly used class of antibiotics worldwide. It is used in the treatment of cancer but 20-26 percent of all patients who receive the antibiotic suffer partial or complete hearing loss. The co-senior author of the study Anthony Ricci stated that their goal is to replace the existing aminoglycosides with ones that are not toxic.
The study found that, N1MS, the new patented antibiotic cured urinary tract infection when tested on mice and was non-toxic to the kidneys too unlike the parent compound. The study presents a promising new approach for generating a new class of novel, non-toxic antibiotics.